Edition:
India

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

1.43EUR
3:19pm IST
Change (% chg)

€-0.03 (-2.33%)
Prev Close
€1.46
Open
€1.47
Day's High
€1.47
Day's Low
€1.42
Volume
42,503
Avg. Vol
118,436
52-wk High
€2.08
52-wk Low
€0.81

Select another date:

Thu, Jul 9 2020

BRIEF-Transgene And Hypertrust Patient Data Care Announce Blockchain Solution For Clinical Trials Of Personalized Healthcare

* TRANSGENE AND HYPERTRUST PATIENT DATA CARE ANNOUNCE SUCCESSFUL GO-LIVE OF THE WORLD’S FIRST BLOCKCHAIN SOLUTION FOR CLINICAL TRIALS OF PERSONALIZED HEALTHCARE

BRIEF-Transgene’s, Bioinvent’s BT-001 Achieves High Tumor Cure Rates In Preclinical Models

* TRANSGENE’S AND BIOINVENT’S BT-001 ACHIEVES OUTSTANDING TUMOR CURE RATES IN PRECLINICAL MODELS

BRIEF-Transgene: New Data From Next-Generation Immunotherapy Platforms

* TRANSGENE PRESENTS PROMISING NEW DATA FROM ITS NEXT-GENERATION IMMUNOTHERAPY PLATFORMS AT AACR 2020

BRIEF-Transgene Reduces Nominal Value To 0.50 From 1 Euro Per Share

* BOARD OF DIRECTORS IMPLEMENTED REDUCTION OF NOMINAL VALUE FROM 1.00 EURO TO 0.50 EURO PER SHARE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Transgene Says Data Confirms High Accuracy Of Cancer Vaccine TG4050

* TRANSGENE AND NEC DEMONSTRATE HIGH ACCURACY OF AI-BASED NEOANTIGEN PREDICTION FOR THE DESIGN OF INDIVIDUALIZED CANCER VACCINE TG4050

BRIEF-Transgene Q1 Operating Revenue Up At 3.0 Million Euros

* IN Q1 OF 2020, TRANSGENE'S CASH BURN WAS EUR 8.0 MILLION, COMPARED TO EUR 7.8 MILLION FOR SAME PERIOD IN 2019

BRIEF-Vaxxel Acquires Transgene's DuckCelt-T17 Cell Line

* VAXXEL ACQUIRES TRANSGENE'S DUCKCELT®-T17 CELL LINE TO DEVELOP INDUSTRIAL-SCALE VACCINES AGAINST RESPIRATORY VIRUSES

Select another date: